Article
Oncology
Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo' Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta
Summary: The study validates the effectiveness of the Molecular International Prognostic Scoring System (IPSS-M) in predicting clinical outcomes of patients with myelodysplastic syndromes (MDS). IPSS-M improves the prognostic discrimination of the Revised International Prognostic Scoring System (IPSS-R) and enhances the accuracy of selecting candidates for hematopoietic stem cell transplantation (HSCT).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Luis E. E. Aguirre, Najla Al Ali, David A. A. Sallman, Somedeb Ball, Akriti G. G. Jain, Onyee Chan, Sara M. M. Tinsley-Vance, Andrew Kuykendall, Kendra Sweet, Jeffrey E. E. Lancet, Eric Padron, Rami S. S. Komrokji
Summary: The Molecular International Prognostic Scoring System (IPSS-M) is a new risk stratification model for myelodysplastic syndromes (MDS) that incorporates mutational data to improve prognostic accuracy. In a large cohort of MDS patients, the IPSS-M was validated and found to be accurate in predicting overall survival (OS), leukemia-free survival (LFS), and leukemic transformation. The model also showed validity in therapy-related and hypoplastic MDS. The use of this tool can lead to more accurate prognostic assessment and optimized therapeutic decision-making in MDS.
Article
Oncology
Wan-Hsuan Lee, Ming-Tao Tsai, Cheng-Hong Tsai, Feng-Ming Tien, Min-Yen Lo, Mei-Hsuan Tseng, Yuan-Yeh Kuo, Ming-Chih Liu, Yi-Tsung Yang, Jui-Che Chen, Jih-Luh Tang, Hsun- Sun, Yi-Kuang Chuang, Liang-In Lin, Wen-Chien Chou, Chien-Chin Lin, Hsin-An Hou, Hwei-Fang Tien
Summary: This study validated the use of the IPSS-M in patients with MDS and compared its prognostic power to the IPSS and IPSS-R. The IPSS-M showed better predictive ability and could help in optimizing therapeutic decision-making for MDS patients. Additional genetic analysis, including KMT2A-PTD, was recommended for accurate IPSS-M categorization of specific patient subgroups.
BLOOD CANCER JOURNAL
(2023)
Article
Oncology
Youshan Zhao, Juan Guo, Sida Zhao, Roujia Wang, Dong Wu, Chunkang Chang
Summary: This study found that bone marrow fibrosis (BMF) is an independent significant prognostic factor for myelodysplastic syndromes (MDS), and adding it to the IPSS-R can improve its predictive capability.
LEUKEMIA & LYMPHOMA
(2023)
Article
Hematology
Yu-Hung Wang, Hsin-An Hou, Chien-Chin Lin, Yuan-Yeh Kuo, Chi-Yuan Yao, Chia-Lang Hsu, Mei-Hsuan Tseng, Cheng-Hong Tsai, Yen-Ling Peng, Chein-Jun Kao, Wen-Chien Chou, Hwei-Fang Tien
Summary: This study revealed the association between immune cell ratios in the bone marrow of MDS patients and prognosis, with the ICSS scoring system able to stratify patients into high, intermediate, and low-risk groups and independently predict prognosis.
Article
Medicine, Research & Experimental
Tong Xing, Zhong-Shi Lyu, Cai-Wen Duan, Hong-Yan Zhao, Shu-Qian Tang, Qi Wen, Yuan-Yuan Zhang, Meng Lv, Yu Wang, Lan-Ping Xu, Xiao-Hui Zhang, Xiao-Jun Huang, Yuan Kong
Summary: Dysfunctional BM EPCs are involved in MDS patients, especially in higher-risk MDS patients, indicating that improving the supporting ability for hematopoiesis and immune regulation ability of BM EPCs may be a promising therapeutic approach for MDS patients.
JOURNAL OF TRANSLATIONAL MEDICINE
(2022)
Article
Multidisciplinary Sciences
Nanfang Huang, Yang Song, Wenhui Shi, Juan Guo, Lingyun Wu, Zheng Zhang, Qi He, Xiao Li, Feng Xu
Summary: DHX9 overexpression in myelodysplastic syndromes (MDS) is associated with poor prognosis and high risk of acute myeloid leukemia (AML) transformation. DHX9 is essential for malignant proliferation of leukemia cells. Suppression of DHX9 increases cell apoptosis and sensitizes cells to chemotherapy. Additionally, DHX9 knockdown inactivates PI3K-AKT and ATR-Chk1 signaling, promotes R-loop accumulation, and leads to R-loop-mediated DNA damage.
Letter
Hematology
Chantana Polprasert, Pimjai Niparuck, Thanawat Rattanathammethee, Sirorat Kobbuaklee, Theerin Lanamtieng, Ponlapat Rojnuckarin
Summary: The study examines the performance of M-IPSS and R-IPSS in Thai patients with MDS. The results show that R-IPSS score can be used for risk stratification in most Thai patients. However, there were discrepancies in re-staging between the two methods in 8% of cases, which may affect treatment decisions.
Article
Hematology
Guillermo Montalban-Bravo, Elias Jabbour, Gautam Borthakur, Tapan Kadia, Farhad Ravandi, Kelly Chien, Naveen Pemmaraju, Danielle Hammond, Xiao Qin Dong, Xuelin Huang, Heather Schneider, Rosmy John, Rashmi Kanagal-Shamana, Sanam Loghavi, Hagop Kantarjian, Guillermo Garcia-Manero
Summary: Lower doses of CPX-351 show promising safety and activity in HR-MDS or CMML patients who have failed HMAs.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Hematology
Yudi Zhang, Junying Wu, Zefeng Xu, Tiejun Qin, Shiqiang Qu, Lijuan Pan, Huijun Wang, Qi Sun, Chengwen Li, Yujiao Jia, Wenyu Cai, Xin Yan, Jingye Gong, Qingyan Gao, Bing Li, Robert Peter Gale, Zhijian Xiao
Summary: The impact of the 2022 International Consensus Classification (ICC) of myelodysplastic syndromes (MDS) needs further investigation. Based on our analysis of data from 989 MDS subjects classified using the 2016 World Health Organization (WHO) criteria, we found that the ICC criteria of MDS-SF3B1 identifies a more homogeneous disease entity than the WHO 2016 criteria of myelodysplastic syndromes with ring sideroblasts (MDS-RS). Additionally, our analysis revealed that MDS, not otherwise specified with single lineage dysplasia (MDS, NOS-SLD) patients have a better prognosis than MDS, NOS with multilineage dysplasia (MDS, NOS-MLD) patients, and that MDS patients with mutated TP53 and MDS/acute myeloid leukemia with mutated TP53 exhibit the shortest survival time. These findings support the use of the ICC for more accurate diagnosis and risk stratification of MDS.
BRITISH JOURNAL OF HAEMATOLOGY
(2023)
Article
Medical Laboratory Technology
Bifa Lai, Yongyu Chen, Minjun Li, Guohua Ye, Huashan Luo, Yonghong Zhong, Xuemin Guo
Summary: Myelodysplastic syndromes (MDS) are a class of myeloid neoplasms characterized by inefficient maturation and differentiation of hematopoietic cells. Diagnosis of MDS is challenging due to its complexity, but establishing an FCM scoring system (FCSS) has been found to be a convenient and affordable approach for diagnosis and prognostic stratification.
CLINICAL LABORATORY
(2022)
Article
Multidisciplinary Sciences
Nerea Berastegui, Marina Ainciburu, Juan P. Romero, Paula Garcia-Olloqui, Ana Alfonso-Pierola, Celine Philippe, Amaia Vilas-Zornoza, Patxi San Martin-Uriz, Raquel Ruiz-Hernandez, Ander Abarrategi, Raquel Ordonez, Diego Alignani, Sarai Sarvide, Laura Castro-Labrador, Jose M. Lamo-Espinosa, Mikel San-Julian, Tamara Jimenez, Felix Lopez-Cadenas, Sandra Muntion, Fermin Sanchez-Guijo, Antonieta Molero, Maria Julia Montoro, Barbara Tazon, Guillermo Serrano, Aintzane Diaz-Mazkiaran, Mikel Hernaez, Sofia Huerga, Findlay Bewicke-Copley, Ana Rio-Machin, Matthew T. Maurano, Maria Diez-Campelo, David Valcarcel, Kevin Rouault-Pierre, David Lara-Astiaso, Teresa Ezponda, Felipe Prosper
Summary: Myelodysplastic syndromes (MDS) are characterized by ineffective hematopoiesis and have increased incidence in older individuals. This study identifies DDIT3 as a driver of dyserythropoiesis in MDS patients and suggests it as a potential therapeutic target to restore efficient erythroid differentiation.
NATURE COMMUNICATIONS
(2022)
Article
Oncology
Qiuni Chen, Yue Chen, Yijing Zhang, Lijuan Zhang, Kankan Chen, Zhengmei He, Chunling Wang, Liang Yu
Summary: This study demonstrates that P-LCR can serve as a biomarker to predict the prognosis of MDS patients, which has significant clinical implications.
FRONTIERS IN ONCOLOGY
(2022)
Article
Oncology
Nikolay Kalitin, Galina Dudina, Natalia Kostritsa, Anastasiya Sivirinova, Aida Karamysheva
Summary: The expression levels of VEGF and VEGFR genes were found to be elevated in patients with MDS compared to healthy volunteers. Analysis of gene expression in MDS patients stratified by risk groups showed increased expression of VEGF-A, VEGFR1, and VEGFR2 with higher risk. Patients with high levels of VEGFR1 expression had significantly different survival times. Thus, VEGF-A/VEGFR1 expression may be important for risk evaluation in MDS patients.
Review
Genetics & Heredity
Chiara Chiereghin, Erica Travaglino, Matteo Zampini, Elena Saba, Claudia Saitta, Elena Riva, Matteo Bersanelli, Matteo Giovanni Della Porta
Summary: Myelodysplastic syndromes (MDS) are clonal diseases driven by a complex combination of genetic mutations, resulting in ineffective hematopoiesis and an increased risk of progression to acute myeloid leukemia. These mutations can be categorized into a limited number of cellular pathways, influencing clinical phenotype, disease progression, and prognosis.
Article
Oncology
Rami S. Komrokji, Sheng Wei, Adam W. Mailloux, Ling Zhang, Eric Padron, David Sallman, Jeffrey E. Lancet, Sara Tinsley, Lisa A. Nardelli, Javier Pinilla-Ibarz, Pearlie K. Epling-Burnette, Alan F. List
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA
(2019)
Review
Hematology
Jung-hoon Lee, Alan List, David A. Sallman
EUROPEAN JOURNAL OF HAEMATOLOGY
(2019)
Article
Biochemistry & Molecular Biology
Valeria Bertagnolo, Silvia Grassilli, Stefano Volinia, Yasamin Al-Qassab, Federica Brugnoli, Federica Vezzali, Elisabetta Lambertini, Maria Palomba, Quirino Piubello, Enrico Orvieto, Cristina Natali, Maria Roberta Piva, Carlo Maria Croce, Silvano Capitani
MOLECULAR CARCINOGENESIS
(2019)
Article
Gastroenterology & Hepatology
Caterina Vicentini, Federica Calore, Giovanni Nigita, Paolo Fadda, Michele Simbolo, Nicola Sperandio, Claudio Luchini, Rita T. Lawlor, Carlo Maria Croce, Vincenzo Corbo, Matteo Fassan, Aldo Scarpa
BMC GASTROENTEROLOGY
(2020)
Letter
Oncology
Maria Rosaria Sapienza, Fabio Fuligni, Federica Melle, Valentina Tabanelli, Valentina Indio, Maria Antonella Laginestra, Giovanna Motta, Saveria Mazzara, Lorenzo Cerroni, Alessandro Pileri, Fabio Facchetti, Marco Paulli, Luciano Cascione, Alessandro Lagana, Emilio Berti, Manuela Ferracin, Claudio Agostinelli, Elena Sabattini, Carlo Maria Croce, Stefano Aldo Pileri
HEMATOLOGICAL ONCOLOGY
(2020)
Article
Multidisciplinary Sciences
Francesca Lovat, Pierluigi Gasparini, Giovanni Nigita, Karilyn Larkin, John C. Byrd, Mark D. Minden, Michael Andreeff, Bing Z. Carter, Carlo M. Croce
Summary: The study found that the loss of both miR-15/16 clusters may act as a potential oncogenic driver in the transition from chronic phase to blast crisis in CML patients.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Editorial Material
Genetics & Heredity
Gerd A. Blobel, Douglas R. Higgs, Jennifer A. Mitchell, Dimple Notani, Richard A. Young
Summary: In this Viewpoint, five experts discuss our biological understanding of super-enhancers, how we can responsibly study their functions, and their opinions on whether names for enhancer clusters are an informative reflection of their functional properties.
NATURE REVIEWS GENETICS
(2021)
Letter
Multidisciplinary Sciences
Liguo Zhang, Alexsia Richards, M. Inmaculada Barrasa, Stephen H. Hughes, Richard A. Young, Rudolf Jaenisch
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Oncology
Maria Rosaria Sapienza, Giuseppe Benvenuto, Manuela Ferracin, Saveria Mazzara, Fabio Fuligni, Claudio Tripodo, Beatrice Belmonte, Daniele Fanoni, Federica Melle, Giovanna Motta, Valentina Tabanelli, Jessica Consiglio, Vincenzo Mazzara, Marcello Del Corvo, Stefano Fiori, Alessandro Pileri, Gaetano Ivan Dellino, Lorenzo Cerroni, Fabio Facchetti, Emilio Berti, Elena Sabattini, Marco Paulli, Carlo Maria Croce, Stefano A. Pileri
Summary: This study described neuronal features in blastic plasmacytoid dendritic cell neoplasm (BPDCN) for the first time, potentially changing our understanding of the disease and leading to new strategies for treatment. The identified neural metastatic inducers in BPDCN may offer therapeutic approaches for patients. The upregulation of neural genes in BPDCN is currently being investigated as therapeutic targets.
Letter
Multidisciplinary Sciences
Liguo Zhang, Alexsia Richards, M. Inmaculada Barrasa, Stephen H. Hughes, Richard A. Young, Rudolf Jaenisch
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2021)
Article
Multidisciplinary Sciences
Felice Pepe, Laura Z. Rassenti, Yuri Pekarsky, Jadwiga Labanowska, Tatsuya Nakamura, Giovanni Nigita, Thomas J. Kipps, Veronica Balatti, Carlo M. Croce
Summary: Chronic lymphocytic leukemia (CLL) is a common adult leukemia characterized by chromosomal aberrations. This study found that some CLL patients have undetected microdeletions, which are closely associated with chromosomal alterations in cancer. These findings may have clinical relevance for successful stratification of patients.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
(2022)
Biographical-Item
Oncology
Gary S. Stein, Carlo M. Croce
Article
Oncology
Alessandro La Ferlita, Nipin Sp, Marina Goryunova, Giovanni Nigita, Raphael E. Pollock, Carlo M. Croce, Joal D. Beane
Summary: Soft-tissue sarcomas (STS), a rare and diverse group of tumors, have various subtypes characterized by differences in tumor biology and clinical outcomes. Small non-coding RNAs (sncRNAs), including miRNAs and tRNA-derived ncRNAs, play important roles in STS tumorigenesis and differentiation. However, the translation of these findings into clinical applications, such as biomarkers or therapeutic targets, remains challenging. This review summarizes the current understanding of sncRNAs in STS, with a focus on liposarcoma, and discusses their potential as novel biomarkers and therapeutic targets.
MOLECULAR CANCER RESEARCH
(2023)
Article
Biochemistry & Molecular Biology
Henry R. Kilgore, Peter G. Mikhael, Kalon J. Overholt, Ann Boija, Nancy M. Hannett, Catherine Van Dongen, Tong Ihn Lee, Young-Tae Chang, Regina Barzilay, Richard A. Young
Summary: This research reveals that different types of intracellular condensates have distinct chemical environments that affect molecular distribution. Machine learning approaches can predict the selective partitioning of molecules in condensates, providing insights for the development of small molecule therapeutics with optimal subcellular distribution and therapeutic benefits.
NATURE CHEMICAL BIOLOGY
(2023)
Meeting Abstract
Oncology
Lucia Casadei, Patricia Sarchet, Luciano Cascione, Giovanni Nigita, Fernanda Costas Casal de Faria, Carlo Maria Croce, Valerie Grignol, Raphael E. Pollock
